Immune Design Corp (IMDZ) Expected to Post Quarterly Sales of $810,000.00

Equities analysts expect Immune Design Corp (NASDAQ:IMDZ) to announce sales of $810,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Immune Design’s earnings. The lowest sales estimate is $400,000.00 and the highest is $1.22 million. Immune Design posted sales of $2.06 million in the same quarter last year, which would indicate a negative year over year growth rate of 60.7%. The company is expected to issue its next quarterly earnings report on Tuesday, March 6th.

On average, analysts expect that Immune Design will report full-year sales of $810,000.00 for the current financial year, with estimates ranging from $7.10 million to $9.00 million. For the next year, analysts expect that the company will post sales of $16.37 million per share, with estimates ranging from $14.73 million to $18.00 million. Zacks’ sales averages are an average based on a survey of research firms that cover Immune Design.

A number of brokerages have recently weighed in on IMDZ. Wells Fargo & Co lowered shares of Immune Design from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $29.00 to $10.00 in a report on Tuesday, October 17th. ValuEngine lowered shares of Immune Design from a “sell” rating to a “strong sell” rating in a report on Saturday, October 21st. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “hold” rating in a report on Friday, November 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $13.06.

In other news, CEO Carlos V. Paya sold 7,970 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $4.17, for a total transaction of $33,234.90. Following the sale, the chief executive officer now directly owns 114,560 shares of the company’s stock, valued at approximately $477,715.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Leo Guthart bought 20,000 shares of the stock in a transaction dated Monday, January 8th. The shares were purchased at an average cost of $3.90 per share, for a total transaction of $78,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 13,959 shares of company stock worth $58,209. 20.70% of the stock is owned by corporate insiders.

Several hedge funds have recently bought and sold shares of IMDZ. Vanguard Group Inc. boosted its stake in shares of Immune Design by 37.9% during the 2nd quarter. Vanguard Group Inc. now owns 524,999 shares of the biotechnology company’s stock worth $5,118,000 after acquiring an additional 144,408 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Immune Design by 1,198.0% during the 2nd quarter. Nationwide Fund Advisors now owns 137,709 shares of the biotechnology company’s stock worth $1,343,000 after acquiring an additional 127,100 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Immune Design by 4.2% during the 3rd quarter. Victory Capital Management Inc. now owns 2,060,234 shares of the biotechnology company’s stock worth $21,324,000 after acquiring an additional 82,670 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Immune Design by 46.9% during the 2nd quarter. Wells Fargo & Company MN now owns 218,700 shares of the biotechnology company’s stock worth $2,132,000 after acquiring an additional 69,813 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in shares of Immune Design by 32.8% during the 2nd quarter. Northern Trust Corp now owns 180,877 shares of the biotechnology company’s stock worth $1,764,000 after acquiring an additional 44,653 shares in the last quarter. 29.38% of the stock is currently owned by institutional investors and hedge funds.

Shares of Immune Design (IMDZ) opened at $3.55 on Thursday. The firm has a market cap of $170.61, a price-to-earnings ratio of -1.67 and a beta of 2.03. Immune Design has a 1-year low of $2.90 and a 1-year high of $13.05.

ILLEGAL ACTIVITY WARNING: “Immune Design Corp (IMDZ) Expected to Post Quarterly Sales of $810,000.00” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2018/02/08/immune-design-corp-imdz-expected-to-post-quarterly-sales-of-810000-00.html.

Immune Design Company Profile

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Get a free copy of the Zacks research report on Immune Design (IMDZ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit